Freaney PM, et al. The role of Sex-Specific risk factors in the risk assessment of atherosclerotic cardiovascular disease for primary prevention in women. Curr Atheroscler Rep. 2020;22(9):2020–07.

Article  Google Scholar 

Freaney PM et al. Premature menopause and 10-Year risk prediction of atherosclerotic cardiovascular disease. JAMA Cardiol, 2021 Sep 15. 6(12).

Cho L et al. Rethinking menopausal hormone therapy: for whom, what, when, and how long?? Circulation, 2023-02-14. 147(7).

Khoudary SRE et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation, 2020-12-22. 142(25).

Freaney PM, et al. Association of premature menopause with coronary artery calcium: the CARDIA study. Volume –11. Circulation: Cardiovascular Imaging; 2021. 11.

Google Scholar 

Zhu D et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health, 2019/11/01. 4(11).

Dam V et al. Association of menopausal characteristics and risk of coronary heart disease: a pan-European case–cohort analysis. Int J Epidemiol, 2019 Feb 22. 48(4).

Muka T et al. Association of age at and time since menopause with cardiovascular outcomes. JAMA Cardiol, 2016/10/01. 1(7).

Shin J et al. Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study. Eur Heart J, 2022/10/21. 43(40).

Maas AHEM et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J, 2021 Jan 25. 42(10).

Anagnostis P et al. Menopause-associated risk of cardiovascular disease. Endocr Connections, 2022 Mar 8. 11(4).

Honigberg MC, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;12/24(24):322.

Google Scholar 

Arnett DK et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of cardiology/american heart association task force on clinical practice guidelines. Circulation, 2019-09-10. 140(11).

Golezar S et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric, 2019-7-4. 22(4).

Qin Y et al. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update, 2015 Aug 4. 21(6).

Chon SJ, Umair Z, Yoon M-S. Premature ovarian insufficiency: past, present, and future. Front Cell Dev Biology. 2021 May;10:9.

La Marca A, et al. Primary ovarian insufficiency: autoimmune causes. Volume 22. Current Opinion in Obstetrics and Gynecology; August 2010. 4.

Silva CA, et al. Autoimmune primary ovarian insufficiency. Autoimmun Rev. 2014;04/01:4–5.

Google Scholar 

Kirshenbaum M, et al. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet. 2019;36(11):2019–08.

Article  Google Scholar 

Hamoda H, Sharma A. Premature ovarian insufficiency, early menopause, and induced menopause. Best Practice & Research Clinical Endocrinology & Metabolism, 2024/01/01. 38(1).

Roeters val, Lennep JE et al. Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis - PubMed. Eur J Prev Cardiol 2016 Jan. 23(2).

Behboudi-Gandevani S et al. Cardiovascular events among women with premature ovarian insufficiency: A systematic review and Meta-Analysis. Rev Cardiovasc Med, 2023 Jul 4. 24(7).

Price MA, et al. Early and surgical menopause associated with higher Framingham risk scores for cardiovascular disease in the Canadian longitudinal study on aging. Volume 4. New York, N.y.): Menopause; 2021 Jan. 5.

Zhu D et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Human Reproduction (Oxford, England), 2020 Jun 20. 35(8).

Valle HAd et al. Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study. Gynecologic Oncology, 2021/09/01. 162(3).

Chen L et al. Protective effect of hormone therapy among women with hysterectomy/oophorectomy. Hum Reprod, 2017/04/01. 32(4).

Lip GYH et al. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J, 1997/10/01. 134(4).

Teede HJ et al. Recommendations from the 2023 international Evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab, 2023 Aug 15. 108(10).

Rotterdam ESHRE, ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004/01/01. 19(1).

Tay CT et al. 2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta‐Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome. Journal of the American Heart Association, 2024-08-20.

Wild RA et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. The Journal of Clinical Endocrinology & Metabolism, 2010/05/01. 95(5).

Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev, 2012 Oct 12. 33(6).

Moran LJ et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2010/07/01. 16(4).

Wekker V et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update, 2020 Sep 30. 26(6).

Gomez JMD et al. Subclinical cardiovascular disease and polycystic ovary syndrome. Fertil Steril, 2022/05/01. 117(5).

Aboeldalyl S et al. The role of chronic inflammation in polycystic ovarian Syndrome—A systematic review and Meta-Analysis. Int J Mol Sci, 2021 Mar 8. 22(5).

Murri M et al. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update, 2013/05/01. 19(3).

Lim SS et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update, 2012/11/01. 18(6).

Merz CNB et al. Cardiovascular disease and 10-Year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Women’s Health 2016 Sep 1. 25(9).

Forslund M et al. <em > Acta Obstetricia et Gynecologica Scandinavica | NFOG Women’s Health Journal | Wiley Online Library</em >. Acta Obstetricia et Gynecologica Scandinavica, 2019/03/01. 98(3).

Hickey M, et al. Managing menopause after cancer. Lancet. 2024;403(10430):984–96.

Article  CAS  PubMed  Google Scholar 

Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with Early-Stage breast Cancer. JNCI Monogr, 2001/12/01. 2001(30).

Lin EM, Aikin JL, Good BC. Premature menopause after Cancer treatment. Cancer Pract, 1999/05/01. 7(3).

Swerdlow AJ et al. Risk of premature menopause after treatment for Hodgkin’s lymphoma. J Natl Cancer Inst, 2014. 106(9).

Sklar CA et al. Premature menopause in survivors of childhood cancer: A report from the childhood Cancer survivor study. JNCI: J Natl Cancer Inst, 2006/07/05. 98(13).

Oktay K, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001.

Article  PubMed  Google Scholar 

Runowicz CD et al. American Cancer society/american society of clinical oncology breast Cancer survivorship care guideline. J Clin Oncol, 2016-2-20. 34(6).

Francis PA et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 2018-07-12. 379(2).

Goodwin PJ et al. Risk of menopause during the first year after breast Cancer diagnosis. J Clin Oncol, 1999-08. 17(8).

Petrek JA et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study - PubMed. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 03/01/2006. 24(7).

Abusief ME et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer, 2010/02/15. 116(4).

Wang K et al. Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies. Sci Rep, 2022 Dec 31. 12(1).

Kang Y-K, et al. The effects of endocrine therapies on lipid profiles in Chinese young women with early breast Cancer. Front Oncol. 2021 Dec;1:11.

Douglas E et al. Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer - PubMed. Clinical breast cancer, 2024 Jun. 24(4).

Polter EJ, et al. Cardiovascular disease with hormone therapy and ovarian suppression in premenopausal breast Cancer survivors. JACC CardioOncol. 2024;6(6):907–18.

Article  PubMed  PubMed Central  Google Scholar 

Khosrow-Khavar F, Azoulay L. Hormonal therapy and cardiovascular health: examining the risk among premenopausal women diagnosed with breast Cancer. JACC CardioOncol. 2024;6(6):919–21.

Article  PubMed  PubMed Central  Google Scholar 

Thomas A et al. Cardiovascular impact of near complete Estrogen deprivation in premenopausal women with breast cancer: the CROWN study. American heart journal, 2023 Oct 26. 267.

Darby SC, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.

Article  CAS  PubMed  Google Scholar 

Parashar S, et al. Cancer Treatment-Related cardiovascular toxicity in gynecologic malignancies: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2023;5(2):159–73.

Article  PubMed  PubMed Central  Google Scholar 

Marchetti C, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150.

Article  PubMed  PubMed Central  Google Scholar 

Beekman MJ, et al. Coronary artery calcium scores after prophylactic premenopausal bilateral Salpingo-Oophorectomy. JACC CardioOncol. 2024;6(6):922–31.

Article  PubMed  PubMed Central  Google Scholar 

Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21.

Article  PubMed  PubMed Central  Google Scholar 

Honigberg MC, et al. Premature menopause, clonal hematopoiesis, and coronary artery disease in postmenopausal women. Circulation. 2021;143(5):410–23.

Article  PubMed  Google Scholar